Back to News
Market Impact: 0.25
Acadia's Remlifanserin Phase 2 Data Support Phase 3 Development In Alzheimer's Psychosis
Source: Nasdaq
Healthcare & Biotech
Acadia Pharmaceuticals announced topline Phase 2 results from the ongoing RADIANT clinical-trial program evaluating remlifanserin for psychosis in patients with Alzheimer's disease. The article does not disclose efficacy, safety, or statistical outcomes, limiting assessment of the trial's financial or regulatory implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
ACAD0.15
More News
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion
- CorMedix stock gains as Heron deal adds four products
- Rezolute at Guggenheim: FDA progress lifts rare-disease hopes
- Hims & Hers earnings up next: Can GLP-1 boom drive profit?
- Harrow earnings on deck as investors eye profitability return